DIA Biosimilars 2013

Parexel

PAREXEL chairman and CEO Josef von Rickenbach elected 2013 ACRO chairman

Thursday, January 10, 2013 02:18 PM

PAREXEL International chairman and CEO, Josef von Rickenbach, has been named 2013 chairman of the Association of Clinical Research Organizations (ACRO).

More... »

Cenduit: Now with Patient Reminders

The CenterWatch Monthly, January 2013

Wednesday, January 2, 2013 01:39 PM

Parexel celebrates 30 years of change, growth

More... »

CRF Health – eCOA Forum

Parexel acquires Liquent

Wednesday, January 2, 2013 09:49 AM

Parexel International has acquired all of the outstanding equity securities of Liquent, a global provider of Regulatory Information Management (RIM) solutions. Liquent provides an integrated platform of software solutions for regulatory submissions and product registration management, as well as a range of complementary business process outsourcing capabilities.

More... »

Perceptive Informatics opens first customer care office in China

Monday, December 10, 2012 10:46 AM

Perceptive Informatics, an e-Clinical solutions provider and subsidiary of PAREXEL International, has opened a customer care office in Shanghai to service biopharmaceutical researchers in China and Taiwan who are using Perceptive’s technology solutions.

More... »

PAREXEL, NTUH to support clinical research in Taiwan

Monday, December 3, 2012 12:17 PM

PAREXEL International, a global biopharmaceutical services provider, and the National Taiwan University Hospital (NTUH) have established a collaboration to provide drug development services in Taiwan.

More... »

PAREXEL International announces CFO transition

Friday, August 10, 2012 02:11 PM

PAREXEL International, a global bio/pharmaceutical services organization, announced that James F. Winschel, Jr., senior vice president and CFO, will transition to the position of executive vice president at PAREXEL upon appointment of a new CFO. 

More... »

German CRO Verum.de opens U.S. office

Wednesday, August 8, 2012 09:24 AM

Verum.de, a German-based CRO, has opened a new office in Carlsbad, Calif.

More... »

PAREXEL appoints Larson as VP of evidence development

Friday, August 3, 2012 12:25 PM

PAREXEL Consulting, a business unit of PAREXEL International and a global consultancy serving the biopharmaceutical and medical device industries, has appointed Leanne R. Larson as vice president of evidence development, a newly created position.

More... »

PAREXEL launches BioPharm Unit to serve smaller sponsors

Wednesday, July 25, 2012 09:28 AM

Boston-based CRO PAREXEL International has launched the PAREXEL BioPharm Unit, a dedicated unit focused solely on the needs of small and mid-sized biopharmaceutical companies to help achieve their development goals.

More... »

PAREXEL partners with Korea Drug Development Fund

Thursday, July 19, 2012 02:29 PM

Boston-based CRO PAREXEL International announced it is the first CRO chosen by the Korea Drug Development Fund (KDDF) to help Korean companies develop and commercialize healthcare products for the global market.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs